ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: Case study of compassionate delamanid use

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 811-815

  Esposito, Susanna ^a   D'Ambrosio, Lia ^b   Tadolini, Marina ^c   Schaaf, H Simon ^d   Luna, Josè Caminero ^e   Marais, Ben ^f   Centis, Rosella ^b   Dara, Masoud ^b   Matteelli, Alberto ^g   Blasi, Francesco ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e Hospital General de Gran Canaria   (Spain)

^f University of Sydney   (Australia)

^g UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; CASE REPORT; CHILD; CHILD HEALTH CARE; CONSULTATION; DRUG MEGADOSE; DRUG USE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTRIC SUCTION; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LARYNGEAL TUBERCULOSIS; LETTER; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SCHOOL CHILD; THORAX RADIOGRAPHY; TUBERCULIN TEST; WORLD HEALTH ORGANIZATION; COMPASSIONATE USE; EPIDEMIC; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ITALY; MEDICAL SOCIETY; MICROBIOLOGY; PROGRAM DEVELOPMENT; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CHILD; COMPASSIONATE USE TRIALS; DISEASE OUTBREAKS; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ITALY; MALE; NITROIMIDAZOLES; OXAZOLES; PROGRAM DEVELOPMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84906890048     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00060414     Document Type: Letter

References (18)

1. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
2. Blasi F, Barnes PJ, Gaga M, et al. Future Directions for the ERS: Presidential plans. Eur Respir J 2013; 42: 875-880.
3. World Health Organization. Global tuberculosis report 2013. Document WHO/HTM/TB/2013.11. Geneva, World Health Organization, 2013.
4. D'Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO TB Consilium: reporting of the initial 10 cases. Eur Respir J 2014; 43: 286-289.
5. Migliori GB, Dara M, de Colombani P, et al. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? Eur Respir J 2012; 39: 1290-1291.
6. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
7. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
8. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
9. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
10. D'Ambrosio L, Dara M, Tadolini M, et al. TB elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
11. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination, dream or reality? The case of Cyprus. Eur Respir J 2014; 44: 543-546.
12. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
13. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
14. Migliori GB, Zellweger JP, Abubakar I, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807-819.
15. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. The 14-day bactericidal activity of combinations of PA-824, bedaquiline, pyrazinamide and moxifloxacin: the path to novel antituberculosis treatment regimens. Lancet 2012; 380: 986-993.
16. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR-/XDR-TB cases: first experience on campassionate use. Eur Respir J 2014; 43: 289-292.
17. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
18. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.